National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Volasertib Research Grant Opportunity – Submit by October 30, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN ORP Grant History
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Octreotide therapy for asymptomatic patients with recurrent, unresectable carcinoid tumors added to Neuroendocrine Tumors Guidelines

The NCCN Clinical Practice Guidelines in Oncology™ for Neuroendocrine Tumors have been updated to include octreotide therapy as a new management option for asymptomatic patients with recurrent, unresectable carcinoid tumors as a category 2A recommendation. This addition is based on recently published interim results of a placebo controlled phase III trial (PROMID).

Other updates include the expansion of the Neuroendocrine Tumor Guidelines to include the management of adrenal gland tumors (including adrenocortical tumors, incidentaloma and adrenal carcinoma). The management of adrenal tumors was previously addressed in the context of MEN-1 syndromes. The updated Neuroendocrine Tumor Guidelines also include recommendations for management of neuroendocrine tumors of unknown primary cancers and surgical principles for management of neuroendocrine tumors.